Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Urethra Cancer
Emory Universityantibody_drug_conjugatePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Urethra Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vinflunine Dr Anders Ullén | Phase 2 | BB |
Carboplatin Jonsson Comprehensive Cancer Center | Phase 2 | BB |
Cis-Diamminedichloroplatinum Ii Jonsson Comprehensive Cancer Center | Phase 1/2 | B |
Pembrolizumab Emory University | Phase 2 | B |
Nivolumab M.D. Anderson Cancer Center | Phase 2 | B |
View all 29 →
Same molecule, other indications
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →